Skip to search formSkip to main contentSkip to account menu

fosaprepitant

Known as: Fosaprepitantum 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

AntiemeticsMorpholinesNeurokinin-1 Receptor Antagonists

Narrower (2)

Fosaprepitant dimeglumineL 785,298

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Evaluation of the Use of Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
A neurokinin-1 (NK1) receptor antagonist is recommended with a 5-HT3 receptor antagonist and dexamethasone for prevention of… 
Review
2018
Review
2018
Systemic hypersensitivity to fosaprepitant – A report of two cases
Fosaprepitant is a widely administered antiemetic used mainly for moderately to highly emetogenic chemotherapy. Local injection… 
2017
2017
Fosaprepitant for the Management of Refractory Pain in a Patient with Cancer-Related Dermatomyositis.
OBJECTIVE Optimal pain management often requires multiple pharmacological interventions with the goal of disrupting the pain… 
2016
2016
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant
Purpose To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning… 
2016
2016
Role of fosaprepitant, a neurokinin Type 1 receptor antagonist, in morphine-induced antinociception in rats
Objectives: Opioids such as morphine form the cornerstone in the treatment of moderate to severe pain. However, opioids also… 
2015
2015
Induction and antagonism of pica induced by teriparatide in rats.
2013
2013
Pemetrexed-induced anaphylaxis
Pemetrexed is a folate antimetabolite approved for the treatment of mesothelioma and locally advanced or metastatic non-squamous… 
Review
2012
Review
2012
Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach
Purpose of reviewThis review summarizes recent developments in the management of gastrointestinal symptoms experienced by cancer… 
2011
2011
Impact of 5-HT3 RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting
Background: It is recommended that patients initiate triple antiemetic therapy with one of the 5-hydroxytryptamine receptor… 
Review
2008
Review
2008
Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting
Background: This paper reviews the existing literature on fosaprepitant, an intravenous neurokinin-1 anatgonist for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)